Indication
Suppression of recurrent herpes simplex infection
Suppression of recurrent herpes simplex infection refers to long-term, continuous antiviral management aimed at preventing or reducing the frequency and severity of repeated clinical outbreaks and asymptomatic viral shedding caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). Read more about Suppression of recurrent herpes simplex infection
106 drugs 73 manufacturers
Drugs that treat it
Common Suppression of recurrent herpes simplex infection therapies.
VALACYCLOVIR (valacyclovir HCl)
FAMCICLOVIR
VALACYCLOVIR (valacyclovir HCl)
ACYCLOVIR
ACYCLOVIR
VALACYCLOVIR (valacyclovir HCl)
ACYCLOVIR SODIUM
ACYCLOVIR SODIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSuppression of recurrent herpes simplex infection refers to long-term, continuous antiviral management aimed at preventing or reducing the frequency and severity of repeated clinical outbreaks and asymptomatic viral shedding caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2).
This clinical state affects mucocutaneous tissues—most commonly the genital tract or orofacial regions—in both immunocompetent individuals with frequent, distressing episodes and immunocompromised populations at risk for prolonged or severe ulcerations.
Pathophysiologically, the virus establishes life-long latency within sensory nerve ganglia following a primary episode, intermittently reactivating and traveling anterograde along peripheral nerves to the epithelium to cause painful vesicular and ulcerative lesions.
- cdc.gov
Suppression of recurrent herpes simplex infection refers to long-term, continuous antiviral management aimed at preventing or reducing the frequency and severity of repeated clinical outbreaks and asymptomatic viral shedding caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) Pathophysiologically, the virus establishes life-long latency within sensory nerve ganglia following a primary episode, intermittently reactivating and traveling anterograde along peripheral nerves to the epithe...
- fda.gov
Suppression of recurrent herpes simplex infection refers to long-term, continuous antiviral management aimed at preventing or reducing the frequency and severity of repeated clinical outbreaks and asymptomatic viral shedding caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) This clinical state affects mucocutaneous tissues—most commonly the genital tract or orofacial regions—in both immunocompetent individuals with frequent, distressing episodes and immunocompromised populations at...
- nih.gov
This clinical state affects mucocutaneous tissues—most commonly the genital tract or orofacial regions—in both immunocompetent individuals with frequent, distressing episodes and immunocompromised populations at risk for prolonged or severe ulcerations Pathophysiologically, the virus establishes life-long latency within sensory nerve ganglia following a primary episode, intermittently reactivating and traveling anterograde along peripheral nerves to the epithelium to cause painful vesicular and ...
Personalize your experience
Follow Suppression of recurrent herpes simplex infection and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.